Edition:
India

ContraFect Corp (CFRX.OQ)

CFRX.OQ on NASDAQ Stock Exchange Capital Market

0.41USD
20 Sep 2019
Change (% chg)

$-0.00 (-0.43%)
Prev Close
$0.42
Open
$0.41
Day's High
$0.44
Day's Low
$0.39
Volume
96,036
Avg. Vol
105,743
52-wk High
$2.60
52-wk Low
$0.27

Latest Key Developments (Source: Significant Developments)

Contrafect Announces CEO Transition
Tuesday, 2 Apr 2019 

April 2 (Reuters) - ContraFect Corp ::CONTRAFECT ANNOUNCES CEO TRANSITION.CONTRAFECT CORP - ROGER J. POMERANTZ WILL SUCCEED STEVEN C. GILMAN, PH.D., WHO IS RETIRING FROM HIS POSITION AS CHAIRMAN AND CEO..CONTRAFECT CORP - ROGER J. POMERANTZ HAS BEEN APPOINTED CHAIRMAN AND CHIEF EXECUTIVE OFFICER OF CONTRAFECT.CONTRAFECT CORP - POMERANTZ WAS MOST RECENTLY CHAIRMAN AND CEO OF SERES THERAPEUTICS.  Full Article

ContraFect Reports Q4 EPS Of $0.07
Thursday, 14 Mar 2019 

March 14 (Reuters) - ContraFect Corp ::CONTRAFECT REPORTS FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.Q4 EARNINGS PER SHARE $0.07.Q4 EARNINGS PER SHARE ESTIMATE $-0.10 -- REFINITIV IBES DATA.AS OF DECEMBER 31, 2018, HAD CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES OF $30.5 MILLION.  Full Article

Antimicrobials Working Group Announces Updates To Leadership Team
Thursday, 17 Jan 2019 

Jan 17 (Reuters) - Antimicrobials Working Group::ANTIMICROBIALS WORKING GROUP ANNOUNCES UPDATES TO LEADERSHIP TEAM.ANTIMICROBIALS WORKING GROUP - APPOINTMENT OF NEW CHAIRMAN, EVAN LOH.ANTIMICROBIALS WORKING GROUP - LOH REPLACES JEFFREY STEIN.  Full Article

ContraFect's Exebacase Improved Clinical Outcomes In Phase 2 Study Compared To Standard Of Care Antibiotics
Monday, 7 Jan 2019 

Jan 7 (Reuters) - ContraFect Corp ::CONTRAFECT’S EXEBACASE (CF-301) IMPROVED CLINICAL OUTCOMES IN STAPHYLOCOCCUS AUREUS BACTEREMIA INCLUDING RIGHT-SIDED ENDOCARDITIS COMPARED TO STANDARD OF CARE ANTIBIOTICS ALONE IN A FIRST-IN-PATIENT PHASE 2 SUPERIORITY STUDY.CONTRAFECT CORP - COMPANY INTENDS TO PROGRESS EXEBACASE TO PHASE 3.CONTRAFECT CORP - EXEBACASE DEMONSTRATED ROBUST SAFETY AND TOLERABILITY PROFILE.CONTRAFECT CORP - AMONG ALL PATIENTS WHO RECEIVED STUDY DRUG, 19.4% OF EXEBACASE PATIENTS AND 14.9% OF PLACEBO PATIENTS DIED.CONTRAFECT - THERE WERE NO SERIOUS TREATMENT EMERGENT ADVERSE EVENTS THAT CO DETERMINED TO BE RELATED TO EXEBACASE.CONTRAFECT CORP - ANNOUNCED POSITIVE TOPLINE RESULTS FROM ITS PHASE 2 CLINICAL TRIAL OF EXEBACASE.  Full Article

ContraFect Corp Files For $100 Mln Mixed Shelf Offering-SEC Filing
Saturday, 1 Dec 2018 

Nov 30 (Reuters) - ContraFect Corp ::CONTRAFECT CORP FILES FOR $100 MILLION MIXED SHELF OFFERING - SEC FILING.  Full Article

Contrafect Q2 Loss Per Share $0.27
Thursday, 9 Aug 2018 

ContraFect Corp ::CONTRAFECT ANNOUNCES SECOND QUARTER 2018 FINANCIAL RESULTS.Q2 LOSS PER SHARE $0.27.Q2 EARNINGS PER SHARE VIEW $-0.10 -- THOMSON REUTERS I/B/E/S.AS OF JUNE 30, 2018, CONTRAFECT HAD CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES OF $33.3 MILLION.  Full Article

ContraFect Corp Prices $10 Mln Public Offering Of Common Stock
Friday, 27 Jul 2018 

July 27 (Reuters) - ContraFect Corp ::CONTRAFECT CORPORATION PRICES $10 MILLION PUBLIC OFFERING OF COMMON STOCK.CONTRAFECT - ANNOUNCED PRICING OF ITS UNDERWRITTEN PUBLIC OFFERING OF 5 MILLION SHARES OF ITS COMMON STOCK AT $2.00/SHARE.  Full Article

ContraFect Corporation Announces Proposed Public Offering Of Common Stock
Friday, 27 Jul 2018 

July 26 (Reuters) - ContraFect Corp ::CONTRAFECT CORPORATION ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.CONTRAFECT CORP - COMMENCED AN UNDERWRITTEN PUBLIC OFFERING OF ITS COMMON STOCK.  Full Article

ContraFect announces Q3 loss per share $0.02
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - ContraFect Corp <22R.SG>:ContraFect announces third quarter 2017 financial results.Q3 loss per share $0.02.ContraFect Corp - ‍As of Sept 30, 2017, had cash, cash equivalents and marketable securities of $52.6 million compared to $35.2 million as of December 31, 2016​.  Full Article